Merck's Clesrovimab Lowers RSV Disease And Hospitalization In Preterm And Full-term Infants
18/10 01:06
(RTTNews) - Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company's investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease du...